产品
编 号：F271683
分子式：C21H18D3Cl2N5OS
分子量：465.41
分子式：C21H18D3Cl2N5OS
分子量：465.41
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2123483-49-6
产品详情
生物活性：
WNK-IN-11-d3 is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11-d3 is effective at regulating cardiovascular homeostasis.
体内研究：
WNK-IN-11 D3 (1.5 mg/kg; p.o.) shows an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability.WNK-IN-11 D3 (30 mg/kg; p.o.) shows significant reductions in systolic blood pressure (SBP) vs untreated mice.WNK-IN-11 D3 (0~100 mg/kg; p.o.) induces dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg.WNK-IN-11 D3 shows trends toward reduction of blood pressure, stroke volume, and total peripheral resistance, while increasing heart rate. WNK-IN-11 D3 shows efficacy in rodent models of hypertension and volume overload.Animal Model:Sprague?Dawley rats
Dosage:1.5 mg/kg
Administration:P.o.
Result:Showed an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability.
Animal Model:FVB mice
Dosage:30 mg/kg
Administration:P.o.
Result:Showed significant reductions in systolic blood pressure (SBP) vs untreated mice.
Animal Model:FVB mice
Dosage:0~100 mg/kg
Administration:P.o.
Result:Induced dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg.
WNK-IN-11-d3 is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11-d3 is effective at regulating cardiovascular homeostasis.
体内研究：
WNK-IN-11 D3 (1.5 mg/kg; p.o.) shows an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability.WNK-IN-11 D3 (30 mg/kg; p.o.) shows significant reductions in systolic blood pressure (SBP) vs untreated mice.WNK-IN-11 D3 (0~100 mg/kg; p.o.) induces dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg.WNK-IN-11 D3 shows trends toward reduction of blood pressure, stroke volume, and total peripheral resistance, while increasing heart rate. WNK-IN-11 D3 shows efficacy in rodent models of hypertension and volume overload.Animal Model:Sprague?Dawley rats
Dosage:1.5 mg/kg
Administration:P.o.
Result:Showed an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability.
Animal Model:FVB mice
Dosage:30 mg/kg
Administration:P.o.
Result:Showed significant reductions in systolic blood pressure (SBP) vs untreated mice.
Animal Model:FVB mice
Dosage:0~100 mg/kg
Administration:P.o.
Result:Induced dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备